Elan invests $20m in Proteostasis to pursue neurology drugs
Irish pharma giant Elan is investing $20m (€14m) in US drug developer Proteostasis Therapeutics to speed the research and development of disease modifying, small molecule drugs and diagnostics for the treatment of neurodegenerative disorders.